Industry 4.0 Technologies for the Manufacturing and Distribution of COVID-19 Vaccines.

Background: The evolutionary stages of manufacturing have led us to conceptualize the use of Industry 4.0 for COVID-19 (coronavirus disease 2019), powered by Industry 4.0 technologies. Using applications of integrated process optimizations reliant on digitized data, we propose novel intelligent netw...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of Primary Care & Community Health Vol. 13; pp. 1 - 6
Autores principales: Sarfraz, Azza, Sarfraz, Zouina, Sarfraz, Muzna, Razzack, Aminah Abdul, Bano, Shehar, Makkar, Sarabjot Singh, Thevuthasan, Sindhu, Paul, Trissa, Sana, Muhammad Khawar, Azeem, Nishwa, Felix, Miguel, Cherrez-Ojeda, Ivan
Formato: tables/charts Journal Article
Publicado: Sage Publications Inc. Jan-Dec2022
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=161704135&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 161704135
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        21501319
        AZBE
      jtl: Journal of Primary Care & Community Health
      issn: 21501319
      maglogo: Y
    pubinfo:
      dt: Jan-Dec2022
      vid: 13
      pid: 344
      pub: Sage Publications Inc.
      place: Thousand Oaks, California
    artinfo:
      ui:
        161704135
        161704135
        161704135
        10.1177/21501319211068638
        161704135
      ppf: 1
      ppct: 5
      formats:
      tig:
        atl: Industry 4.0 Technologies for the Manufacturing and Distribution of COVID-19 Vaccines.
      aug:
        au:
          Sarfraz, Azza
          Sarfraz, Zouina
          Sarfraz, Muzna
          Razzack, Aminah Abdul
          Bano, Shehar
          Makkar, Sarabjot Singh
          Thevuthasan, Sindhu
          Paul, Trissa
          Sana, Muhammad Khawar
          Azeem, Nishwa
          Felix, Miguel
          Cherrez-Ojeda, Ivan
        affil: Larkin Community Hospital, South Miami, FL, USA
      sug:
        subj:
          Artificial Intelligence
          COVID-19 Vaccines Supply and Distribution
          COVID-19 Prevention and Control
          Digital Technology
          Biosensing Techniques
          Industry
          Health Services Accessibility
          Developing Countries
          Digitizers
          Low and Middle Income Countries
          Computer-Aided Design
          Biometrics
          Conceptual Framework
          Biosensors
          Blockchain
          Public Health
      ab: Background: The evolutionary stages of manufacturing have led us to conceptualize the use of Industry 4.0 for COVID-19 (coronavirus disease 2019), powered by Industry 4.0 technologies. Using applications of integrated process optimizations reliant on digitized data, we propose novel intelligent networks along the vaccine value chain. Vaccine 4.0 may enable maintenance processes, streamline logistics, and enable optimal production of COVID-19 vaccines. Vaccine 4.0 Framework: The challenge in applying Vaccine 4.0 includes the requirement of large-scale technologies for digitally transforming manufacturing, producing, rolling-out, and distributing vaccines. With our framework, Vaccine 4.0 analytics will target process performance, process development, process stability, compliance, quality assessment, and optimized maintenance. The benefits of digitization during and post the COVID-19 pandemic include first, the continual assurance of process control, and second, the efficacy of big-data analytics in streamlining set parameter limits. Digitization including big data-analytics may potentially improve the quality of large-scale vaccine production, profitability, and manufacturing processes. The path to Vaccine 4.0 will enhance vaccine quality, improve efficacy, and compliance with data-regulated requirements. Discussion: Fiscal and logistical barriers are prevalent across resource-limited countries worldwide. The Vaccine 4.0 framework accounts for expected barriers of manufacturing and equitably distributing COVID-19 vaccines. With amalgamating big data analytics and biometrics, we enable the identification of vulnerable populations who are at higher risk of disease transmission. Artificial intelligence powered sensors and robotics support thermostable vaccine distribution in limited capacity regions, globally. Biosensors isolate COVID-19 vaccinations with low or limited efficacy. Finally, Vaccine 4.0 blockchain systems address low- and middle-income countries with limited distribution capacities. Conclusion: Vaccine 4.0 is a viable framework to optimize manufacturing of vaccines during and post the COVID-19 pandemic.
      pubtype: Academic Journal
      doctype:
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N